

Atty Dkt. No.: STAN-201
USSN: 09/960,708

LISTING OF CLAIMS

Below is a listing of the claims pending in the subject application. No amendments are made in this response.

Claims:

- 1-7. (Canceled)
8. (Previously Presented) A method of inhibiting angiogenesis/vascular development in a host having a condition associated with unwanted angiogenesis, said method comprising:
systemically administering to said host an effective amount of a Ca²⁺/calcineurin/NF-ATc inhibitory agent to inhibit angiogenesis/vascular development in said host having a condition associated with unwanted angiogenesis.
9. (Original) The method according to Claim 8, wherein said agent is an NF-ATc antagonist.
10. (Original) The method according to Claim 9, wherein said agent inhibits phosphorylation of NF-ATc.
11. (Original) The method according to Claim 10, wherein said agent inhibits NF-ATc phosphorylation by binding to calcineurin.
- 12-14. (Canceled)
15. (Previously Presented) A method of inhibiting tumor growth in a host having a neoplastic disease condition, said method comprising:
systemically administering to said host having a neoplastic disease condition an effective amount of a Ca²⁺/calcineurin/NF-ATc inhibitory agent to inhibit tumor

Atty Dkt. No.: STAN-201
USSN: 09/960,708

growth in said host.

16. (Original) The method according to Claim 15, wherein said agent is an NF-ATc antagonist.
17. (Original) The method according to Claim 16, wherein said agent inhibits phosphorylation of NF-ATc.
18. (Original) The method according to Claim 16, wherein said agent inhibits NF-ATc phosphorylation by binding to calcineurin.
- 19-34. (Canceled)
35. (Previously Presented) The method according to Claim 8, wherein said agent is FK506 or a synthetic mimetic thereof.
36. (Previously Presented) The method according to Claim 8, wherein said agent is rapamycin or a synthetic mimetic thereof.
37. (Previously Presented) The method according to Claim 8, wherein said agent is a cyclosporin.
38. (Previously Presented) The method according to Claim 37, wherein said cyclosporin is cyclosporin A.
39. (Previously Presented) The method according to Claim 38, wherein said cyclosporin is a synthetic derivative or mimetic of cyclosporin A.
40. (Previously Presented) The method according to Claim 15, wherein said agent is FK506 or a synthetic mimetic thereof.

Atty Dkt. No.: STAN-201
USSN: 09/960,708

41. (Previously Presented) The method according to Claim 15, wherein said agent is rapamycin or a synthetic mimetic thereof.
42. (Previously Presented) The method according to Claim 15, wherein said agent is a cyclosporin.
43. (Previously Presented) The method according to Claim 42, wherein said cyclosporin is cyclosporin A.
44. (Previously Presented) The method according to Claim 42, wherein said cyclosporin is a synthetic derivative or mimetic of cyclosporin A.
45. (Canceled)
46. (Previously Presented) A method of inhibiting angiogenesis/vascular development in a host having a condition associated with unwanted angiogenesis, said method comprising:
administering to said host an effective amount of a cyclosporin to inhibit angiogenesis/vascular development in a host having a condition associated with unwanted angiogenesis.
47. (Previously Presented) A method of inhibiting tumor growth in a host having a neoplastic disease condition, said method comprising:
administering to said host an effective amount of a cyclosporin to inhibit tumor growth in said host having a neoplastic disease condition.